Poverty, HIV and other disease burdens, coupled with common mental disorders including alcohol and other substance use disorders, posttraumatic stress disorder, clinical and postnatal depression, distress, and anxiety, impact how caregivers meet the needs of children. When mental health is not consi...dered or addressed, there can be a significant impact on an individual, their family and the community.
more
Supplement Article
www.jaids.com J Acquir Immune Defic Syndr Volume 78, Supplement 1, August 15, 2018
Masangane Case Study
The Vesper Society commissioned ARHAP to do research on the integrated Masangane HIV/AIDS programme affiliated with the Moravian Church in Eastern Cape, South Africa. Completed in 2006, this study aimed to understand the role of the religious health assets of the Masangane ART ...programme for public health, as a model for a replicable response to HIV/AIDS. A crucial aspect of this research involved teasing out what value is added to this programme by its faith-based nature. Field work for this case study consisted of more than 20 key informant interviews of various stakeholders: Masangane staff and management; church leaders; health seekers; donors and health providers. Health seekers also answered 77 questionnaires and were involved in two focus groups.
more
Prepared by NGOs: “Legalife-Ukraine”, “Insight”, “Positive Women”, and “Svitanok”
For the submission to the 66th CEDAW Session Geneva, Switzerland
13 February 2017 - 03 March 2017
A Systematic Review and Meta-analysis
Clinical Infectious Diseases® 2016;62(12):1586–94
The COVID-19 pandemic has affected everyone, including key populations at higher risk of HIV. And the gains made against other infectious diseases, including HIV, are at risk of being reversed as a result of disruptions caused by COVID-19. This is the background to a new report published by FHI 360,... in collaboration with UNAIDS, which gives advice on how to minimize the impacts of COVID-19 on key populations.
more
Second Edition
AIDS Medicines and diagnostics services
July 2015
May 9, 2022.Since the onset of the COVID-19 pandemic, a large number of clinical trials have been planned and developed to assess the effectiveness and safety of various interventions that could prevent hospitalizations and progression to severe disease in people infected with SARS-CoV-2. Currently,... the WHO and the PAHO recommend the use of corticosteroids, tocilizumab, baricitinib, and casirivimab e imdevimab (the latter in seronegative COVID-19 patients) and propose the use of sotrovimab, casirivimab/imdevimab, and molnupiravir in patients with non-severe illness who are at high risk for complications
more
Guidance
Second Edition
Monitoring and Evaluation
Diagnostics 2019, 9(4), 204; https://doi.org/10.3390/diagnostics9040204
Impact Evalution Report 61